Role of curcumin in idiopathic pulmonary arterial hypertension treatment: A new therapeutic possibility

Medical Hypotheses

Volumn 81, Issue 5, 2013, Pages 923-926

  Bronte, Enrico ^a   Coppola, Giuseppe ^a   Di Miceli, Riccardo ^b   Sucato, Vincenzo ^a   Russo, Antonio ^a   Novo, Salvatore ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; CYTOKINE; ENDOTHELIN 1 DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHODIESTERASE INHIBITOR; PIPERINE; PROSTANOID; TRANSFORMING GROWTH FACTOR BETA; TURMERIC;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DIET; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME INACTIVATION; HEART FAILURE; HUMAN; LUNG VASCULAR RESISTANCE; NONHUMAN; PULMONARY ARTERY; PULMONARY HYPERTENSION; QUALITY OF LIFE; SIGNAL TRANSDUCTION; TREATMENT PLANNING;

CURCUMIN; HUMANS; HYPERTENSION, PULMONARY; MODELS, BIOLOGICAL; NF-KAPPA B; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; VASCULAR RESISTANCE;

EID: 84886770418     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.08.016     Document Type: Article

References (26)

1. McLaughlin V.V., Archer S.L., Badesch D.B., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of cardiology foundation task force on expert consensus documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009, 119(16):2250-2294.
2. Price L.C., Wort S.J., Perros F., et al. Inflammation in pulmonary arterial hypertension. Chest 2012, 141(1):210-221.
3. Schermuly R.T., Ghofrani H.A., Wilkins M.R., Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011, 8(8):443-455.
4. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008, 118(7):2372-2379.
5. McLaughlin V.V., Davis M., Cornwell W. Pulmonary arterial hypertension. Curr Probl Cardiol 2011, 36(12):461-517.
6. Simonneau G., Robbins I.M., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54(Suppl. 1):S43-S54.
7. Ulrich S., Fischler M., Speich R. Update on therapies for pulmonary hypertension. Swiss Med Wkly 2007, 137(5-6):73-82.
8. Rosenkranz S. Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol 2007, 96(8):527-541.
9. Zhou H., Beevers C.S., Huang S. The targets of curcumin. Curr Drug Targets 2011, 12(3):332-347.
10. Epstein J., Sanderson I.R., Macdonald T.T. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 2010, 103(11):1545-1557.
11. Bharti A.C., Donato N., Aggarwal B.B. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003, 171(7):3863-3871.
12. Strimpakos A.S., Sharma R.A. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 2008, 10(3):511-545.
13. Baeuerle P.A., Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994, 12:141-179.
14. Tak P.P., Firestein G.S. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001, 107(1):7-11.
15. Munford R.S., Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001, 163(2):316-321.
16. Abe Y., Hashimoto S., Horie T. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 1999, 39(1):41-47.
17. Srimal R.C., Dhawan B.N. Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol 1973, 25(6):447-452.
18. Kumar A., Dhawan S., Hardegen N.J., Aggarwal B.B. Curcumin (diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem Pharmacol 1998, 55(6):775-783.
19. Lao C.D., Ruffin M.T., Normolle D., et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006, 17(6):10.
20. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21(4B):2895-2900.
21. Aggarwal B.B., Harikumar K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009, 41(1):40-59.
22. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., Srinivas P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998, 64(4):353-356.
23. Sharma R.A., Gescher A.J., Steward W.P. Curcumin: the story so far. Eur J Cancer 2005, 41(13):1955-1968.
24. Vareed S.K., Kakarala M., Ruffin M.T., et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 2008, 17(6):1411-1417.
25. Suresh M.V., Wagner M.C., Rosania G.R., et al. Pulmonary administration of a water-soluble curcumin complex reduces severity of acute lung injury. Am J Respir Cell Mol Biol 2012, 47(3):280-287.
26. Sharma R.A., Euden S.A., Platton S.L., et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004, 10(20):6847-6854.